Back to Basics?

Analyst Tim Anderson says that Pfizer could cut back to become strictly a drug discovery firm. To do so, the company would have to strip itself of "divisions accounting for $32 billion of its $67 billion in sales," adds Matthew Herper at Forbes. Anderson says these "extremely bold" moves would be greeted warmly by investors, though Pfizer has not made any commitments one way or the other.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.